Lexicon Pharmaceuticals' CEO Discusses LX4211 Top-line Data From Phase 2b Trial (Transcript)

Lexicon Pharmaceuticals, Inc. (LXRX)

Special Call

June 25, 2012 10:00 a.m. ET

Executives

Wade Walke - Senior Director, Communications and Investor Relations

Arthur Sands - President and Chief Executive Officer

Brian Zambrowicz - Executive Vice President and Chief Scientific Officer

Pablo Lapuerta - Senior Vice President of Clinical Development and Chief Medical Officer

Jeff Wade - Executive Vice President and Chief Financial Officer

Analysts

Cory Kasimov - JPMorgan

Alan Carr - Needham & Company

Liana Moussatos - Wedbush Securities

David Friedman - Morgan Stanley

Kevin Kedra - Gabelli & Company

Nicholas Bishop - Cowen and Company

Presentation

Operator

Thank you for holding. Welcome to the Lexicon Pharmaceuticals conference call and webcast to discuss LX4211 top-line Phase 2b study results. At this time all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at Lexicon’s request.

At this time I would like to introduce your host for today's call, Wade Walke, Senior Director of Communications and Investor Relations. Please go ahead, Dr. Walke.

Wade Walke

Good morning, and welcome to the Lexicon Pharmaceuticals conference call and webcast. I am Wade Walke and with me today are Dr. Arthur Sands, Lexicon’s President and Chief Executive Officer; Dr. Brian Zambrowicz, Lexicon’s Executive Vice President and Chief Scientific Officer; Dr. Pablo Lapuerta, Lexicon’s Senior Vice President of Clinical Development and Chief Medical Officer.

We expect that you have seen the copy of our press release that was distributed this morning. During this call we will review the information provided in the release, provide further detail on the top line results from the LX4211 Phase 2b study, then use the remainder of our time to answer your questions. If you would like to view the slides for today's call, please access the Lexicon website at www.lexpharma.com, you will see a link on the home page for today's webcast.

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

4 Smaller Biotech Names Worth Researching

7 Things to Watch in Biotech Now

These 3 Biotech Stocks Are Already Moving Wildly on Thursday